Trial Profile
A clinical trial of myvacTM in patients with solid tumors
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 16 Oct 2018
Price :
$35
*
At a glance
- Drugs Cancer vaccine (Primary)
- Indications Head and neck cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions
- 16 Oct 2018 New trial record
- 24 Sep 2018 According to a Transgene media release, the company expects to initiate this trial in 2019.